Skip to main content

Agile Therapeutics Inc

AGRXDelisted Jun 3, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001261249

Agile Therapeutics Inc was delisted on Jun 3, 2024; its insiders filed their last Form 4 on Aug 26, 2024; 21 institutions reported holding it in 13F filings for Q4 2023, worth $496.2K in total; no superinvestor held it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
21
Q4 2023, +4 vs. previous quarter
13F value
$496.2K
Reported value at the end of Q4 2023
Superinvestors holding
0
At the end of Q4 2023

Superinvestors holding AGRX, Q4 2023

Go to the superinvestors tab

No superinvestor reported holding AGRX at the end of Q4 2023.

Latest insider trades

Open-market purchases and sales by Agile Therapeutics Inc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 29, 2022 (view filing)8:30 AM ETAug 263 daysAltomari AlfredChief Executive OfficerPPurchase+50.0K$0.45+$22.5K+348.6%64.3K after
Oct 15, 2021 (view filing)4:05 PM ETOct 132 daysEdelman Joseph and 2 others10% OwnerPPurchase+5.73M$0.85+$4.87M+36.0%21.7M after
Oct 15, 2021 (view filing)4:05 PM ETOct 132 daysEdelman Joseph and 2 others10% OwnerPPurchase+2.69M–––2.69M afterDerivative
Oct 14, 2021 (view filing)Oct 131 dayReilly DennisChief Financial OfficerPPurchase+58.8K––+26.0%285.1K after
Oct 14, 2021 (view filing)Oct 131 dayReilly DennisChief Financial OfficerPPurchase+29.4K–––29.4K afterDerivative
Oct 14, 2021 (view filing)Oct 131 dayAltomari AlfredChief Executive OfficerPPurchase+58.8K––+11.4%573.7K after
Oct 14, 2021 (view filing)Oct 131 dayAltomari AlfredChief Executive OfficerPPurchase+29.4K–––29.4K afterDerivative
Jul 29, 2021 (view filing)Jul 29Same dayAltomari AlfredChief Executive OfficerPPurchase+26.2K$1.26+$33.0K+5.4%514.9K after
Jul 28, 2021 (view filing)Jul 271 dayReilly DennisChief Financial OfficerPPurchase+50.0K$1.08+$54.0K+28.4%226.3K after

Top 10 13F holders, Q4 2023

The largest institutional positions in Agile Therapeutics Inc at the end of Q4 2023; share changes are against Q3 2023.

See all 21 holders
Institutions holding AGRX in Q4 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Armistice Capital, LLC108,000$210.6K0.01%+10,000+10.2%Added
Renaissance Technologies LLC59,200$115.0K0.00%+59,200New
Vanguard Group Inc20,477$39.9K0.00%+20,477New
Citadel Advisors LLC19,247$37.5K0.00%+6,422+50.1%Added
Geode Capital Management, LLC13,748$26.8K0.00%−42−0.3%Reduced
State Street Corp10,843$21.1K0.00%00.0%Unchanged
JPMorgan Chase & Co7,712$15.0K0.00%+4,243+122.3%Added
BlackRock Inc.5,745$11.2K0.00%−295−4.9%Reduced
Tower Research Capital LLC (TRC)3,276$6.39K0.00%+1,085+49.5%Added
Advisory Services Network, LLC2,020$3.94K0.00%+2,020New

Holders of 5% or more of AGRX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Agile Therapeutics Inc.

See all 1 holders and filings
Largest holders of AGRX from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Mastrangeli Doug13G5.10%350.0K sharesNewAug 26, 20241 filingAug 26, 2024SEC